Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Lymphoma × eribulin × Clear all

Phase

Status

Terminated 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 10 Neoplasm Metastasis 2 Urinary Bladder Neoplasms 1 Recurrence 1 Neoplasms 1 Lymphoma 1 Inflammatory Breast Neoplasms 1 HER-2 Positive Breast Cancer 1 Adenocarcinoma 1

Interventions

Rituximab 54 Cyclophosphamide 46 fludarabine phosphate 21 fludarabine 20 Filgrastim 19 Methotrexate 17 Vincristine 16 Radiotherapy 16 Melphalan 16 Etoposide 16 Doxorubicin 15 Cytarabine 13 Whole-Body Irradiation 12 Tacrolimus 12 Prednisone 12 Mycophenolic Acid 12 Gemcitabine 12 Cyclosporine 12 Antilymphocyte Serum 12 Peripheral Blood Stem Cell Transplantation 11 Lenalidomide 11 Busulfan 9 Granulocyte Colony-Stimulating Factor 8 Dexamethasone 8 Cord Blood Stem Cell Transplantation 8 sargramostim 7 Vorinostat 7 Methylprednisolone 7 Bortezomib 7 Alemtuzumab 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02082626 2020-03-10

ERIBULIN

University of Oklahoma

Phase 1 Terminated

Lymphoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡